The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical study on Compound Kushen Injection combined with sorafenib and interleukin-2 in treatment of advanced kidney cancer
Author(s): 
Pages: 1502-1505
Year: Issue:  12
Journal: World Phytomedicines

Keyword:  Compound Kushen InjectionSorafenib Tosylate TabletsRecombinant Human Interleukin-2 for injectionadvanced kidney cancer;
Abstract: Objective To explore the clinical effect of Compound Kushen Injection combined with sorafenib and interleukin-2 in treatment of advanced kidney cancer. Methods Patients(86 cases) with advanced kidney cancer in Shengjing Hospital of China Medical University from July 2013 to March 2015 were enrolled in this study. According to the different treatment plan, patients were divided into treatment(43 cases) and control(43 cases) groups. The patients in the control group were po administered with Sorafenib Tosylate Tablets 2 h after meals, 400 mg/time, twice daily. They were also iv administered with Recombinant Human Interleukin-2 for injection by PICC tube during 2-3 h, 3 × 105 U/m2 added into normal saline 500 m L. The patients were treated with Recombinant Human Interleukin-2 for 4 d in one week, and 4 weeks were as one course. The patients in the treatment group were iv administered with Compound Kushen Injection by PICC tube on the basis of control group, 20 m L added into 0.9% normal saline 250 m L, once daily, 14 d in one course. One course of treatment included 4 weeks, and two groups were treated for three courses. The clinical efficacy and improvement of life quality in two groups were evaluated, and the changes of immune function in two groups before and after treatment were compared. Results After treatment, the total effective rate of control group was 20.93%, and the clinical benefit rate was 65.12%, while the total effective rate of treatment group was 41.86%, and the clinical benefit rate was 83.72%, and there were differences between two groups(P < 0.05). The improvement rate of life quality in the control and treatment groups were 67.44% and 86.05%, respectively, and there were differences between two groups(P < 0.05). After treatment, CD3+, CD4+, and CD4+/CD8+ cell in two groups were increased, and the level of CD(8+ cell was lower, and the difference was statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Compound Kushen Injection combined with sorafenib and interleukin-2 has the good clinical effect in treatment of advanced kidney cancer, and can improve the life quality and immune function, which has a certain clinical application value.
Related Articles
No related articles found